Company intelligence / Profile preview

Mazal Plant Pharmaceuticals

Ownership: Private
Development stage: Other

Overview

Mazal developed three main programs using a proprietary whole plant approach. The lead asset, MAHDL01 for cholesterol management, received FDA IND clearance in May 2005 and was preparing to enter Phase I/II trials at that time. No published results or further clinical progress are available after that date.

Therapeutic areas: OncologyCardiovascularNeurology
Modalities: Whole plant pharmaceuticals (plant-derived drug compositions)Small molecules derived from whole plants
Industry: Biotech

Drug pipeline

1 asset

MAHDL01

Preclinical

Beyond the preview

Go deeper on Mazal Plant Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mazal Plant Pharmaceuticals.

Explore the full profile